HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00716274

Atomoxetine for ADHD

It tested atomoxetine for ADHD.

ADHD, DyslexiaDrugFrom 10 Years to 16 Years
The study in practice

Understand this study

Who was this study for?

Listed age limits: 10 years to 16 years.

Listed locations
New Haven, United StatesSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study information

Study start dateSeptember 2008
Recruitment status
Completed
Enrollment listed in the registry
110
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 10 Years to 16 Years
Official registry ID
NCT00716274
Official title
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine and Placebo.

Who was this study for?

Listed age limits: 10 years to 16 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.